Summary
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
History
Rigel was founded in 1997 and has grown to become a leading biotechnology company focused on discovering, developing and commercializing novel, small molecule drugs. Since 1997, Rigel has discovered, developed and brought to market a portfolio of drugs intended for the treatment of conditions such as rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. In 2015, the company's lead product, fostamatinib, became the first novel therapy approved by the U.S. Food and Drug Administration (FDA) for adults suffering from chronic immune thrombocytopenia (ITP). The company currently has several compounds in one or more phases of clinical development.
Mission
Our mission is to discover, develop and commercialize small molecule drugs to treat a range of disease areas, including inflammation, oncology, and autoimmune.
Vision
Our vision is to be at the vanguard of progress in small molecule drug discovery and development, demonstrating our commitment to bringing transformative medicines to those afflicted by serious diseases.
Key Team
Mr. David A. Santos (Exec. VP & Chief Commercial Officer)
Mr. Joseph Lasaga (Exec. VP of Corp. Devel.)
Ms. Julie Patel (Sr. VP of HR)
Dr. Esteban S. Masuda (Exec. VP of Research)
Mr. Tarek Sallam (VP of Marketing)
Recognition and Awards
Rigel has earned several awards and recognition for its innovation, including being named to FierceBiotech’s Top 15 Biotechs to Watch, Forbes Magazine’s Most Innovative Growth Companies, and to the Deloitte Technology Fast 500™
References
United States 